Skip to main content

Nanoparticle vaccine for COVID-19


Nanoparticle vaccine for COVID-19

Before the pandemic, Stanford University biochemist Peter S. Kim's lab focused on developing vaccines for HIV, Ebola, and pandemic influenza. But, within days of closing their campus lab space as part of COVID-19 precautions, they turned their attention to a vaccine for SARS-CoV-2, the virus that causes COVID-19. Although the coronavirus was outside the lab's specific area of expertise, they and their collaborators have managed to construct and test a promising vaccine candidate.

"Our goal is to make a single-shot vaccine that does not require a cold-chain for storage or transport. If we're successful at doing it well, it should be cheap too," said Kim, who is the Virginia and D. K. Ludwig Professor of Biochemistry. "The target population for our vaccine is low- and middle-income countries."

Their vaccine, detailed in a paper published Jan. 5 in ACS Central Science, contains nanoparticles studded with the same proteins that comprise the virus's distinctive surface spikes. In addition to being the reason why these are called coronaviruses -- corona is Latin for "crown" -- these spikes facilitate infection by fusing to a host cell and creating a passageway for the viral genome to enter and hijack the cell's machinery to produce more viruses. The spikes can also be used as antigens, which means their presence in the body can trigger an immune response.

Nanoparticle vaccines balance the effectiveness of viral-based vaccines with the safety and ease-of-production of subunit vaccines. Vaccines that use viruses to deliver the antigen are often more effective than vaccines that contain only isolated parts of a virus. However, they can take longer to produce, need refrigerated, and are more likely to cause side effects. Nucleic acid vaccines -- like the Pfizer and Moderna mRNA vaccines that have recently been authorized for emergency use by the FDA -- are even faster to produce than nanoparticle vaccines. Still, they are expensive to manufacture and may require multiple doses. Initial tests in mice suggest that the Stanford nanoparticle vaccine could produce COVID-19 immunity after just one dose.

The researchers are also hopeful that it could be stored at room temperature and investigate whether it could be shipped and stored in a freeze-dried powder form. By comparison, the furthered vaccines, along with in development in the United States, all need to be stored at cold temperatures, ranging from approximately 8 to -70 degrees Celsius (46 to -94 degrees Fahrenheit).

"This is really early stage, and there is still lots of work to be done," said Abigail Powell, a former postdoctoral scholar in the Kim lab and lead author of the paper. "But we think it is a solid starting point for what could be a single-dose vaccine regimen that doesn't rely on using a virus to generate protective antibodies following vaccination."

The researchers continue to improve and fine-tune their vaccine candidate, to move it closer to initial clinical trials in humans.

Spikes and nanoparticles

The spike protein from SARS-CoV-2 is quite large, so scientists often formulate abridged versions simpler to make and easier to use. After closely examining the spike, Kim and his team chose to remove a section near the bottom.

To complete their vaccine, they combined this shortened spike with ferritin nanoparticles -- an iron-containing protein -- which has been previously tested in humans. Before the pandemic, Powell had been working with these nanoparticles to develop an Ebola vaccine. Together with scientists at the SLAC National Accelerator Laboratory, the researchers used cryo-electron microscopy to get a 3D image of the spike ferritin nanoparticles to confirm that they had the proper structure.

For the mouse tests, the researchers compared their shortened spike nanoparticles to four other potentially useful variations: nanoparticles with full spikes, full spikes or partial spikes without nanoparticles, and a vaccine containing just the section of the spike that binds to cells during infection. Testing the effectiveness of these vaccines against the actual SARS-CoV-2 virus would have required the work to be done in a Biosafety Level 3 lab, so the researchers instead used a safer pseudo-coronavirus modified to carry SARS-CoV-2's spikes.

The researchers determined the potential effectiveness of each vaccine by monitoring levels of neutralizing antibodies. Antibodies are blood proteins produced in response to antigens; neutralizing antibodies are the specific subset of antibodies that actually act to prevent the virus from invading a host cell.

After a single dose, the two nanoparticle vaccine candidates both resulted in neutralizing antibody levels at least twice as high as those seen in people who have had COVID-19, and the shortened spike nanoparticle vaccine produced a significantly higher neutralizing response than the binding spike or the full spike (non-nano particle) vaccines. After a second dose, mice with the shortened spike nanoparticle vaccine had the highest levels of neutralizing antibodies.

Looking back at this project, Powell estimates that the time from inception to the first mouse studies was about four weeks. "Everybody had a lot of time and energy to devote to the same scientific problem," she said. "It is a very unique scenario. I don't really expect I'll ever encounter that in my career again."

"What's happened in the past year is really fantastic, in terms of science coming to the fore and being able to produce multiple different vaccines that look like they're showing efficacy against this virus," said Kim, who is the senior author of the paper. "It normally takes a decade to make a vaccine, if you're even successful. This is unprecedented."

Vaccine access

Although the team's new vaccine is intended specifically for populations that may have more difficulty accessing other SARS-CoV-2 vaccines, it is possible, given the rapid progress of other vaccine candidates, that it will not be needed to address the current pandemic. In that case, the researchers are prepared to pivot again and pursue a more universal coronavirus vaccine to immunize against SARS-CoV-1, MERS, SARS-CoV-2, and future coronaviruses not yet known.

"Vaccines are one of the most profound achievements of biomedical research. They are an incredibly cost-effective way to protect people against disease and save lives," said Kim. "This coronavirus vaccine is part of work we're already doing -- developing vaccines that are historically difficult or impossible to develop, like an HIV vaccine -- and I'm glad that we're in a situation where we could potentially bring something to bear if the world needs it."

Additional Stanford co-authors include Kaiming Zhang, a research scientist in bioengineering; Mrinmoy Sanyal, a research scientist in biochemistry; Shaogeng Tang, a postdoctoral fellow in biochemistry; Payton Weidenbacher, a graduate student in chemistry; Shanshan Li, postdoctoral researchers in bioengineering; Tho Pham, clinical assistant professor in pathology at Stanford Medicine (also affiliated with the Stanford Blood Center in Palo Alto); and Wah Chiu, the Wallenberg-Bienenstock Professor at Stanford and the SLAC National Accelerator Laboratory, and professor of bioengineering and of microbiology and immunology. A researcher from Chan Zuckerberg Biohub is also a co-author. Kim is a Stanford Bio-X member, the Maternal & Child Health Research Institute (MCHRI), and the Wu Tsai Neurosciences Institute, and a faculty fellow of Stanford ChEM-H. He is also affiliated with the Chan Zuckerberg Biohub. Chiu is a Stanford Bio-X member and the Wu Tsai Neurosciences Institute and a faculty fellow of Stanford ChEM-H.

This work was funded by MCHRI, the Damon Runyon Cancer Research Foundation, the National Institutes of Health, the Virginia and D. K. Ludwig Fund for Cancer Research, and Chan Zuckerberg Biohub.


Popular posts from this blog


Cracking coconut oil’s "health halo" Thanks to marketing strategies that tout coconut oil as healthy, many people consider this solid, white fat a portion of healthy food. But a new analysis confirms what nutrition experts have said for years: Coconut oil raises harmful LDL cholesterol (a well-known contributor to heart disease) much more than other vegetable oils. The study, published online March 10, 2020, by the journal  Circulation , pooled findings from 16 trials involving a total of 730 people. Most of the trials lasted one to two months and compared coconut oil consumption with that of other fats, including other vegetable oils such as soybean, safflower, canola, and olive oils. Compared with these vegetable oils, coconut oil raised LDL cholesterol by 10 points, on average. An editorial accompanying the study states "In culinary practice, coconut oil should not be used as regular cooking oil, although it can be used sparingly for flavor or texture.

Autophagy:The Body's Anti-aging process

Autophagy: The body's Anti-aging process Autophagy is how the body removes and recycles dangerous, and damaged organelles and particles, as well as pathogens, from inside cells, thus aiding your immune system and greatly reducing your risk of developing cancer, heart disease, chronic inflammation, osteoarthritis, and neurological disorders such as depression and dementia. Autophagy makes us physiologically more efficient by getting rid of defective parts, promoting healthy metabolism, stopping cancerous growths, and preventing metabolic disorders such as diabetes and obesity --- which means that by boosting your body's autophagy, you dampen inflammation, slow down the aging process, reduce your risk of developing certain diseases, and optimize your biological function. The autophagy process is activated by intermittent fasting and calorie restriction. Intermittent fasting and calorie restriction turn up the autophagy dial, increasing protein turnover and cellular repai


How to lower your cholesterol without drugs You can begin to reduce your “bad” LDL cholesterol by making a few simple changes in your diet. If your cholesterol is creeping upward, your doctor has probably told you that diet and exercise — the traditional cornerstones of heart health — could help to bring it down. And if you’d prefer to make just one change at a time, you might want to begin with your diet. A major 2012 analysis of several controlled trials involving hundreds of men and women found that dietary changes reduced LDL and total cholesterol while exercise alone had no effect on either. (However, adding aerobic exercise did enhance the lipid-lowering effects of a heart-healthy diet.) The people in the studies followed a variety of diets, from the Mediterranean to low-fat to low-calorie. However, the most effective diets substituted foods with cholesterol-lowering power for those that boost cholesterol. According to Kathy McManus, director of the Department of Nutrition at Bri